Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 04 2021 - 4:01PM
Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company
focused on developing transformative therapies for rare, monogenic
central nervous system disorders, today announced that Bruce
Goldsmith, Ph.D., president and chief executive officer will
present a company overview at the J.P Morgan 39th Annual Healthcare
Conference being held virtually on Monday, January 11, 2021 at
7:30am ET.
A live webcast of the presentation will be available on the
Investors & Media section of Passage Bio’s website at
investors.passagebio.com and will remain active for 30 days.
About Passage BioAt Passage Bio (Nasdaq: PASG),
we are on a mission to provide life-transforming gene therapies for
patients with rare, monogenic CNS diseases that replace their
suffering with boundless possibility, all while building lasting
relationships with the communities we serve. Based in Philadelphia,
PA, our company has established a strategic collaboration and
licensing agreement with the renowned University of Pennsylvania’s
Gene Therapy Program to conduct our discovery and IND-enabling
preclinical work. This provides our team with access to a broad
portfolio of gene therapy candidates and future gene therapy
innovations that we then pair with our deep clinical, regulatory,
manufacturing and commercial expertise to rapidly advance our
robust pipeline of optimized gene therapies into clinical testing.
As we work with speed and tenacity, we are always mindful of
patients who may be able to benefit from our therapies. More
information is available at www.passagebio.com.
For further information, please contact:
Investors:Sarah McCabe and Zofia MitaStern Investor Relations,
Inc.212.362.1200sarah.mccabe@sternir.com zofia.mita@sternir.com
Media:Gwen FisherPassage
Bio215.407.1548gfisher@passagebio.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Oct 2023 to Oct 2024